Literature DB >> 23848260

Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.

Marcelo E Bigal1, Sarah Walter, Alan M Rapoport.   

Abstract

Calcitonin gene-related peptide (CGRP) is a ubiquitous neuropeptide found at the very centers of the migraine process, both centrally and peripherally. It has been under careful study for approximately 25 years. Several CGRP-receptor antagonists are being evaluated for acute treatment of episodic migraine. Three monoclonal antibodies are being studied for prevention of episodic migraine, and 1 monoclonal antibody is being studied for prevention of chronic migraine. In this review, we discuss the role of CGRP in normal physiology and the consequences of CGRP inhibition for human homeostasis. We then review the current state of development for CGRP-receptor antagonists and CGRP monoclonal antibodies. We close by speculating on the potential clinical role of CGRP antagonism in the acute and preventive treatment of episodic and chronic migraine.
© 2013 American Headache Society.

Entities:  

Keywords:  antibodies; calcitonin gene-related peptide; chronic migraine; migraine

Mesh：

Substances：

Year:  2013        PMID： 23848260     DOI： 10.1111/head.12179

Source DB:  PubMed          Journal:  Headache        ISSN： 0017-8748            Impact factor:   5.887


  51 in total

Review 1.  The TRPA1 channel in migraine mechanism and treatment.

Authors:  S Benemei; C Fusi; Gabriela Trevisan; Pierangelo Geppetti
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 2.  From blast to bench: A translational mini-review of posttraumatic headache.

Authors:  Laura S Moye; Amynah A Pradhan
Journal:  J Neurosci Res       Date:  2017-02-02       Impact factor: 4.164

Review 3.  Therapeutic antibodies against CGRP or its receptor.

Authors:  Marcelo E Bigal; Sarah Walter; Alan M Rapoport
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

4.  CGRP receptor activity in mice with global expression of human receptor activity modifying protein 1.

Authors:  Keegan J Bohn; Baolin Li; Xiaofang Huang; Bianca N Mason; Anne-Sophie Wattiez; Adisa Kuburas; Christopher S Walker; Peiyi Yang; Jianliang Yu; Beverly A Heinz; Kirk W Johnson; Andrew F Russo
Journal:  Br J Pharmacol       Date:  2017-04-22       Impact factor: 8.739

5.  Calcitonin gene-related peptide can be selected as a predictive biomarker on progression and prognosis of knee osteoarthritis.

Authors:  Tianhua Dong; Heping Chang; Fei Zhang; Wei Chen; Yanbin Zhu; Tao Wu; Yingze Zhang
Journal:  Int Orthop       Date:  2015-03-28       Impact factor: 3.075

Review 6.  Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.

Authors:  Marcelo E Bigal; Sarah Walter
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 7.  TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine.

Authors:  Sarah Walter; Marcelo E Bigal
Journal:  Curr Pain Headache Rep       Date:  2015-03

Review 8.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

9.  Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.

Authors:  Zdravko Lacković; Boris Filipović; Ivica Matak; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2016-01       Impact factor: 8.739

Review 10.  Does exercise make migraines worse and tension type headaches better?

Authors:  Nada Ahmad Hindiyeh; John Claude Krusz; Robert Paul Cowan
Journal:  Curr Pain Headache Rep       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.